Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • HCV infection does not significantly alter the virologic or immunologic response to effective antiretroviral therapy[Miller 2005]
  • Adverse Events
    • Interferon- and ribavirin-free DAA regimens recommended for the treatment of HCV infection in patients coinfected with HIV have shown to be highly tolerable with generally favorable safety profiles
    • The most important safety consideration for HCV therapy in patients with HCV/HIV coinfection are established and potential drug–drug interactions between HCV DAAs and antiretroviral agents
    Drug–Drug Interactions

    Action required